Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2021-05-19 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
北京君合（成都）律师事务所关于成都先导药物开发股份有限公司2020年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedures of the 2020 Annual General Meeting (AGM) of Chengdu Lead Drug Development Co., Ltd. It details the convening, attendance, voting procedures, and resolutions passed at the AGM. The document does not contain financial statements or detailed financial performance data but focuses on the legal compliance and voting results of the AGM. This matches the description of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length (6466 characters) and content confirm it is not a full annual report or financial report but a legal opinion and voting results announcement related to the AGM.
2021-05-19 Chinese
成都先导药物开发股份有限公司关于2020年年度股东大会更正补充公告
AGM Information Classification · 95% confidence The document is a correction and supplementary announcement regarding the 2020 Annual General Meeting (AGM) of Chengdu Lead Drug Development Co., Ltd. It details changes to the meeting location, confirms the date and voting procedures, and includes an authorization letter for proxy voting. The content focuses on the logistics and procedural updates for the AGM rather than the meeting materials or presentations themselves. The document length is short (2193 characters) and it serves as an announcement about the AGM rather than the AGM materials or minutes. Therefore, it fits best under the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about the AGM itself.
2021-05-14 Chinese
成都先导药物开发股份有限公司2020年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled '2020 年年度股东大会会议资料' which translates to '2020 Annual General Meeting (AGM) Materials'. It contains detailed agenda, meeting notices, reports from the board and supervisory committee, financial reports, and voting procedures related to the 2020 AGM of 成都先导药物开发股份有限公司. The content includes meeting instructions, agenda items, board and supervisory reports, financial data summaries, and voting details, all typical of materials prepared for an AGM. It is not the actual annual report (10-K) or financial statements themselves but the materials prepared and distributed for the AGM. The document length is substantial (15,000 characters), indicating it is the full AGM materials, not just an announcement or a brief summary. Therefore, the correct classification is AGM Information (AGM-R).
2021-05-11 Chinese
成都先导药物开发股份有限公司关于自愿披露获得药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Chengdu Lead Drug Development Co., Ltd. regarding the voluntary disclosure of obtaining implicit approval for a drug clinical trial from the National Medical Products Administration. It details the approval of clinical trial applications for the drug HG146 for new indications. The document includes information about the drug, its development status, and risk warnings to investors. It is a regulatory announcement about a clinical trial approval, not a financial report, earnings release, or management discussion. The document length is short (1422 characters) and it is an announcement of a regulatory event related to drug approval. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-04-29 Chinese
成都先导2021年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2021. The report is unaudited as stated in the text. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2021
2021-04-28 Chinese
成都先导药物开发股份有限公司独立董事关于公司对外担保情况的专项说明
Audit Report / Information Classification · 90% confidence The document is a special statement by independent directors regarding the company's external guarantees for the year 2020. It references regulatory notices from the China Securities Regulatory Commission about external guarantees and confirms no external guarantees or violations occurred in 2020. The document is short (670 characters) and appears to be a standalone statement or certification rather than a full audit or annual report. It does not contain financial statements or detailed audit results but is a formal attestation by independent directors. This fits best under Audit Report / Information (AR) as it relates to a specific audit-related statement on external guarantees, not a full annual report or other category. The presence of independent directors' signatures further supports this classification. FY 2020
2021-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.